Nov 1, 2011
ALLEGAN, Mich., Nov. 1, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that its partner, PharmaForce/Luitpold Pharmaceuticals, received final approval for Epinastine HCl ophthalmic solution, 0.05%, a generic version of Elestat®. Perrigo will commence shipment of the product immediately.
Elestat® is a sterile ophthalmic solution containing epinastine that is indicated for the prevention of ocular itching associated with allergic conjunctivitis. Estimated annual brand sales for the product prior to generic market formation were $30 million, according to Wolters Kluwer data.
Perrigo's Chairman and CEO Joseph C. Papa stated, "Perrigo is excited to launch another new product in the ophthalmic category, as part of our extended topical strategy. This product is another example of Perrigo's commitment to expand our portfolio and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare products."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Perrigo Company
CONTACT: Arthur J. Shannon, Vice President, Investor Relations and Communication, +1-269-686-1709, firstname.lastname@example.org, or Bradley Joseph, Senior Manager, Investor Relations and Communication, +1-269-686-3373, email@example.com
Web Site: http://www.perrigo.com